Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switch-BB: Switch from mirabegron to vibegron for residual overactive bladder symptoms
jRCT1031190024Completed
- Sponsor
- Kissei Pharmaceutical Co., Ltd.
- Start
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of vibegron in overactive bladder (OAB), sponsored by Kissei Pharmaceutical Co., Ltd. Primary endpoint: Change in OABSS total score. Started Jun 2019; status: completed.
02
Drugs
vibegron
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on jRCT1031190024.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1031190024.